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Abstract Proteomics-based identification of biomarkers
for fetal abnormalities and pregnancy complications in
amniotic fluid (AF) has made significant progress in the
past 5 years. This is attributed mainly to advances in
mass spectrometry-based proteomic technologies that
enable new strategies for discovering biomarkers from
complex biological fluids in a high-throughput and
sensitive manner. These markers, although they still need
to be verified, are diagnostic and may in the future
provide targets for therapeutic intervention. In the current
review we focus on the emergence of proteomics as a
major platform technology in studying AF and developing
biomarkers for fetal aneuploidies and pregnancy-related
disorders.
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Introduction
Over the last decade, research mainly focused on the
molecular characterization of various biological systems and
disease states. The human genome consists of approximately
21.000 genes and provides researchers with valuable gene
expression data. It is the human proteome, however, that
actually regulates cellular function and ultimately determines
the phenotype. The proteome is dynamic and changes
constantly under the control of a particular set of intrinsic
and extrinsic stimuli. This process is complicated because of
the ability of the gene to produce more than one protein, post-
translational processing and structural modifications which
lead to functional proteins [1].
Proteomic analysis has become a popular platform for
the discovery of biomarkers for various pathologies using
several types of biological fluids or tissues [2–4]. Proteo-
mic approaches are already used in some fields of medical
research, including liver, heart disease, certain forms of
cancer and pregnancy research [5–7].
Pregnancy and proteomics
Pregnancy progression and delivery rely on complex
fetomaternal processes that involve interactions of intracel-
lular and extracellular factors including hormones, adhesion
molecules, growth factors and immunomodulators [8].
Maternal physiological processes and immune responses
are modified to allow the semi-allogenic fetus to survive
within the uterine environment [9]. Fetal tissues, on the
other hand, serve as endocrine organs and produce a wide
range of proteins that enter maternal and fetal circulation
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and have diverse effects on various systems [10]. An
intricate balance of these substances is required throughout
pregnancy and in cases of gestational disease or fetal
genetic abnormalities this balance may be disturbed.
Identification of proteins specific to pregnancy is likely to
contribute to the comprehension of the underlying patho-
physiology and to the discovery of relevant biomarkers for
fetal aneuploidies and pregnancy complications [3, 4, 11].
If detected in early pregnancy or before the development of
clinical symptoms they can be used as suitable disease
markers, whereas those detected at later stages are likely to
be more specific and may be closely related to the
phenotype of the disease. Biomarkers can also improve
management of pregnancy, determine the outcome and
allow plan for possible complications in delivery.
This article aims to summarize applications of proteo-
mic technology on amniotic fluid (AF), the most
important and specific body fluid related to gestation.
With the advent of high resolution ultrasonography, AF
is accessible for extensive studies and application of
proteomic methods has yielded significant information
regarding the physiology of reproduction and pathological
conditions related to pregnancy. A considerable amount of
data are now available on several aspects including pregnancy
progression and delivery.
Physiology of amniotic fluid
Amniotic fluid (AF) is fundamental for the normal develop-
ment of the human fetus during pregnancy. The amniotic sac,
which contains the embryo, forms about 12 days after
conception. AF immediately begins to fill the sac and at this
time it consists mainly of water supplied by the mother [12,
13]. After approximately 12 weeks, fetal urine makes up
most of the fluid. At 15 weeks of gestation, the volume
of AF is about 200 ml, at 24 weeks about 800 ml and
continues to increase until the 28 to 32 week of pregnancy.
After that time, the level of AF generally stays the same until
the 37–40 weeks when the level declines [14].
AF is a rich source of biomarkers for the diagnosis of
fetal genetic abnormalities and pregnancy complications.
The biochemical composition of the AF is complex, varies
throughout pregnancy and is mainly related to functions of
the different fetal and amniotic compartments. It contains
proteins, amino acids, carbohydrates, hormones, lipids and
electrolytes. In contrast to other biological fluids, like
plasma and serum, AF has a low protein concentration and
relatively high carbohydrate and lipid content. Many of the
protein molecules present in AF are structurally glycocon-
jugates and are protected against proteolytic attack from the
extracellular matrix proteases [15–17]. Many proteins
detected in the AF are already present at a very early stage
of gestation, whereas others are detected only at the end of
pregnancy. The concentration of a given protein in the AF
is governed not only by fetal, placental, or maternal
synthesis and degradation, but also by exchanges between
the mother and the fetus through the placenta. Feto-
maternal transfer of proteins involves several different
mechanisms. Consequently, the concentration of each
AF protein results from a balance between opposing
dynamic metabolic and physiological processes which
proceed simultaneously.
Because of these particular characteristics several varia-
bles need to be considered for AF effective proteomic
analysis, including sample preparation and handling,
protein pre-fractionation, affinity depletion of highly abun-
dant proteins, isolation of subproteomes (e.g. glycoproteome
and phosphoproteome), multidimensional chromatographic
separation etc. Prior to proteome analysis it is necessary
to measure protein concentration of the sample. Two
methods seem to be effective and are widely used: a)
precipitation of the protein content using an organic
solvent, mainly acetonitrile and b) concentration of the sample
with ultracentrifugal filters with a molecular weight cut
off <10 kDa [18–20].
Mass spectrometry-based proteomics (MS) has become
the method of choice for the analysis of AF. The advantages
of MS include sensitivity, resolution, speed and high
throughput, but at the expense of generating huge amount
of data to be analyzed using more advanced bioinformatics.
The choice of MS-based strategy is strongly dependent on
the biological question to be addressed, and also on the
specificity and the amount of material available. Proteomic
techniques used for the analysis of AF could be divided in
two major groups, namely «top-down» and «bottom-up»
[21, 22]. In the former, intact proteins are characterized
directly via MS, whereas in the latter, proteins are first
digested and the resulting peptides are then analyzed to
identify and sometimes quantify proteins (the «bottom-up»
approach is frequently used with liquid chromatography).
Techniques employing gels and gel independent methods
have been applied for the analysis of AF. The most common
and widely accepted approach relies upon a coordinated use of
2-DE, image analysis, mass spectrometric protein identifica-
tion, and bioinformatics/database construction [23, 24]. Gel-
free electrophoresis, which allows sample fractionation by
isoelectric focusing, trypsin digestion of the fragments and
finally peptide analysis by capillary LC-MS/MS was also
introduced for the analysis of AF [18, 25].
The normal human amniotic fluid proteome
Published proteome analyses of human AF were originally
limited to cultured cells. Specifically, Nilsson et al. by
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direct LC analysis of digested samples, followed by Fourier
transform ion cyclotron resonance MS, identified 43
proteins in the 15th-week AF [26]. Oh et al. investigated
metabolic enzymes in cultured AF cells and reported on a
possible screening method for metabolic enzymes and
metabolism related proteins which might form the basis
for future metabolic screening when amniocentesis is
carried out [27]. Jin et al. investigated the influence of the
exposure of AF cells to N-methyl-N’-nitro-N-nitrosoguani-
dine, known to induce DNA damage, leading to chromo-
some rearrangements and reported significant changes in
the proteome profile [28].
Since 1997 the proteomic profile of the normal human
AF was determined by several groups. Liberatori et al.
identified human AF proteins in uncultured AF supernatant
by immunoblot analysis and reported a 2D-E protein map
of human AF obtained at the 17th-week of gestation, when
AF is most commonly obtained for prenatal diagnosis of
chromosomal abnormalities by amniocentesis [24]. Tsangaris
et al. using 2D-E coupled with MALDI-TOF-MS,
published a protein database of normal human AF cells
consisting of 432 different gene products [29]. In another
study, Tsangaris et al., reported on the proteomic profile of
the AF supernatant comprising of 136 different gene
products (Fig. 1) [30]. Queloz et al. compared the proteomic
profiles of normal AF obtained at 17 and 40 weeks of
pregnancy using 2-DE and silver staining, as well as 2D-
DIGE [31]. Results showed that some proteins were more
abundant early in pregnancy, while others were over-
expressed at term, suggesting that the protein profile of AF
is dynamic and changes occur during development. These
observations are particularly important when biomarkers for
a specific condition are identified. In 2007, Cho et al.
reported on the most extensive protein profile of the second
trimester normal human AF, which is comprised of 1026
unique gene products from 842 different genes [32]. It is
interesting to note that the protein list reported in this study
includes hCG-β chain, AFP and inhibin A, which are
currently used as serum screening markers for Down
syndrome (DS).
Amniotic fluid proteomic studies for the detection
of fetal aneuploidies
In an attempt to identify novel biomarkers for fetal chromo-
somal abnormalities several proteomic studies have been
performed using AF samples obtained from cases known to
carry chromosomally abnormal fetuses. Although in prelim-
inary proteomic studies, no relevant protein markers had been
Fig. 1 Two dimensional gel
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validated for prenatal diagnosis of fetal pathological con-
ditions, recent publications have demonstrated that proteomic
tools could be of potential clinical value.
An AF fingerprint was generated by Wang et al. using a
large variety of surface arrays in 20 samples obtained from
pregnant women known to carry an aneuploid fetus [33].
Following application of pattern recognition algorithms, it
was possible to successfully identify aneuploidies, based on
distinct biomarker peaks that segregated at 2.65–7.0 kd, but
it was not possible to differentiate between the various
chromosome abnormalities.
Since DS is the most common chromosomal abnormality
with a prevalence of 1 in 732 fetuses, the majority of studies
focus on the detection of biomarkers for this congenital
anomaly. Oh et al. identified metabolic changes in AF samples
coming from pregnancies carrying DS fetuses in a study
concerning use of proteomic techniques for the identification
of metabolic changes [27]. Specifically he noted significant
derangement in the carbohydrate and amino acid handling,
purine and intermediary metabolism as well as miscellaneous
metabolic pathways. Tsangaris et al. identified biomarkers in
AF samples from pregnancies with DS fetuses and chromo-
somally normal ones [34]. This comparison revealed seven
proteins differentially expressed in samples obtained from
pregnancies with DS fetuses as compared to controls. Alpha-
1-microglobulin, collagen alpha 1 (I) chain, collagen alpha 1
(III) chain, collagen alpha 1 (V) chain d and basement
membrane-specific heparin sulfate proteoglycan core protein
were increased in cases with DS, whereas insulin-like growth
factor-binding protein was decreased by 40% compared to
chromosomally normal fetuses. In the same study, splicing
factor arginine/ serine-rich protein was present only in AF
samples coming from cases with DS syndrome fetuses and
was completely absent in the chromosomally normal ones. It
is important to note that genes encoding for these proteins
are located on chromosomes other than chromosome 21, but
their expression is possibly regulated by transcription factors
located on chromosome 21.
In another study the same group identified in AF
samples obtained from pregnancies with Turner syndrome
fetuses seven biomarkers for Turner syndrome, using the
same MS based technology [35]. Serotransferin, lumican,
plasma retinol-binding protein and apolipoprotein A-I were
increased in Turner syndrome, while kininogen, prothrom-
bin, and apolipoprotein A-IV were decreased. Interestingly,
APOA1 and plasma retinol-binding protein were also
altered in AF obtained from cases with Klinefelter
syndrome fetuses [36].
Mange et al. described a proteomic approach combining
ProteinChip technology that allowed screening for fetal
aneuploidies in AF with prediction accuracy of approximately
90%, that might be helpful for the rapid clinical management
of high-risk pregnancies for fetal aneuploidies [37].
In 2009 Wang et al. identified proteins differentially
expressed in AF coming from pregnancies with DS and
trisomy 18 fetuses [38]. The proteins with significant
differential expression in samples obtained from cases with
DS fetuses were APOA1, SERPINA3, prealbumin (trans-
thyretin, TTR) and transferrin (TF). Levels of apolipoprotein
A1, AP-3mu and antitrypsin were significantly decreased in
trisomy-18 AF, whereas placental protein-14 was increased.
On the other hand, apolipoprotein A1 was decreased in
trisomy-21 AF, but antitrypsin, prealbumin and transferrin
were increased. Proteins differentially expressed in samples
coming from women carrying trisomy 18 fetuses were
involved in immune processes, dysfunction of skin pigmen-
tation and platelet disorders, whereas those of DS were
associated with dysfunctional lipid and cholesterol metabo-
lism, processes of metal ion transport, adenosine triphosphate
metabolism and energy coupled protein transport.
Cho et al. used two-dimensional LC, followed by MS/MS,
to analyze AF of chromosomally normal and DS-affected
pregnancies [39]. A total of 542 proteins were identified by
LTQ-Orbitrap mass spectrometer and data were compared
semi-quantitatively by spectral counting. Based on the
spectral count differences between the two groups analyzed,
after normalization, 60 candidate biomarkers that showed
greater than two-fold increase or decrease in concentration in
the presence of DS fetuses were identified. The differential
expression of amyloid precursor protein and tenascin-C were
verified by ELISA and both showed a two-fold increase, on
average, in DS-AF samples as compared to controls.
Seven proteins from chromosome 21 were identified in
this study and all showed increased expression in DS AF
as compared to controls, supporting the long-standing
«gene-dosage hypothesis».
Recently, Park et al. analyzed AF samples collected in
the 2nd trimester of pregnancy by liquid chromatography-
electrospray ionization-tandem mass spectrometry (LC-
ESI-MS/MS) [40]. Thirty new AF proteins were identified
in this study and 44 AF proteins were found to be
differentially expressed in DS and normal cases. Six of
these proteins were unique to DS AF, while 11 were unique
to chromosomally normal cases. In addition, 19 proteins
were down-regulated and 8 were up-regulated in DS cases
with varying fold changes. Western blot analysis confirmed
the LC-ESI-MS/MS data that detection of Apolipoprotein
combination with A-II and AFP could represent a potential
tool for diagnosing DS cases.
Proteome studies in pregnancy related complications
Pregnancy related disorders such as intra uterine growth
restriction (IUGR), pre-eclampsia (PE), preterm labor
(PTL) and intra amniotic infection (IAI) contribute signif-
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icantly to maternal and fetal mortality. Each of these
disorders is considered to have multifactorial etiology, has
a prevalence of 5–10%, and is often difficult to predict [41,
42]. Although several pathways for the pathogenesis of
pregnancy complications have been proposed, the basic
molecular mechanisms that modulate these events remain
incompletely understood. Discovery of clinically and
biologically relevant biomarkers able to reveal key patho-
genic pathways and predict pregnancies at risk for antenatal
fetal damage is a priority. Proteomics provides a unique
opportunity to fill this gap.
Biomarkers for the early prediction of pre-eclampsia
PE is a complex disorder of pregnancy, which is character-
ized by hypertension and proteinuria that develop after
20 weeks of gestation in previously normotensive women
[43]. Up to date, no therapeutic approaches are available for
either treatment or prevention of PE. This rapidly progres-
sive syndrome is diagnosed when the mother develops
hypertension and proteinuria. The only cure for PE is
delivery, resulting in a third of the babies being born
prematurely. It is estimated that more than 8 million women
are affected each year and over 70.000 maternal deaths
occur worldwide. Therefore, biomarkers are important to
help understand disease, potentially identify women at risk
to improve their outcomes and design therapies.
There are only a few reports in the literature on the use
of proteomic analysis in pre-eclampsia. In an effort to
elucidate the pathogenesis of PE, Vascotto et al. compared
the amniotic fluid proteomic maps of five PE patients with
those of five controls by two-dimensional electrophoresis
(2D-E), followed by peptide mapping and tandem mass
spectrometric analysis [44]. Results showed that trans-
thyretin and retinol-binding protein were present in AF
samples of women who had developed PE and control
women as a mixture of dimeric and post-translationally
modified monomeric forms. Although the nature of these
forms was similar in both groups, women who had
developed PE showed a significant increase in the amount
of monomeric proteins with respect to controls, possibly
due to the higher oxidative stress associated with PE.
In another study, Park et al. using SELDI TOF MS
identified proapolipoprotein A-I and a functionally obscure
peptide, SBBI42 (peak X) that can be used to distinguish PE
from chronic hypertension and normotensive controls [45].
Wang et al. reported leptin as a predictive marker for PE,
since significant elevation of this protein was measured in
AF samples 2 months earlier than the appearance of
symptoms [46]. In another study the same group reported
increased levels of F2-isoprostane in AF in the women who
later developed pre-eclampsia [47]. Since F2-isoprostane is
a marker of oxidative stress and lipid peroxidation this finding
may be used as a guide for antioxidant supplementation to
reduce the risk and/or severity of preeclampsia.
Potential biomarkers for the early diagnosis of preterm
labor and intra amniotic infection
PTL and adverse neonatal outcome are strongly associated
with the presence of clinically undetectable IAI.
Use of surface-enhanced laser desorption ionization time
of flight (SELDI-TOF) analysis coupled with LC-MS/MS
for AF profiling revealed differences in the peak intensity
in AF samples obtained from women with PTL and sub-
clinical IAI [48]. Based on the results of this study,
calgranulin B and a proteolytic fragment IGFBP-1 have
been proposed as candidate biomarkers for IAI. It is of
special interest that the same differences in protein
expression were also found in maternal serum, allowing
for non-invasive detection of IAI. The role of IGFBP-1
biological activity in IAI was recently confirmed by Bujold
et al. using a combination of techniques involving 2D
chromatography, MS and immunoassays [49].
Buhimschi et al. profiled specific proteins for inflamma-
tion in AF and reported on the existence of four biomarkers
(defensins-2 and −1, calgranulin-C, and calgranulin-A),
which were called the «MR score», that can quickly and
accurately detect potentially dangerous infections in preg-
nant women and predict premature birth [50–52]. The «MR
score» presents a gradient of disease activity and progresses
from absent to mild and severe inflammation. If no
biomarkers are present, then the pregnancy is considered
to be uncomplicated while an «MR score» of three or four
is highly predictive of adverse pregnancy outcome. Thus,
biomarkers that constitute the «MR score» can identify
patients who might benefit from in utero interventions in a
modern diagnostic–therapeutic framework.
Romero et al. using liquid chromatography tandem
mass spectrometry with isobaric labeling (iTRAQ) of the
AF proteome of women with PTL identified proteins
differentially regulated in women with IAI and in those
without IAI who delivered preterm [22]. Importantly,
many novel proteins were found to be up-regulated in the
AF of patients with PTL and IAI including leukocyte
elastase precursor, Thymosin-like 3, and 14-3-3 protein
isoforms. Moreover, they observed differential expression
of proteins in AF of patients who delivered preterm in the
absence of IAI as compared to those with PTL who
delivered at term including Mimecan precursor, latent-
transforming growth factor b-binding protein isoform 1 L
precursor, and Resistin.
Park et al. found altered expression of Calgranulin A and
B in human amnion and AF samples obtained from
pregnant women infected with Ureaplasma urealyticum,
but not in any of the patients without infection [53].
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Ruetschi et al. analyzed AF from pregnant women with
clinical signs of PLT with or without IAI/infection using
SELDI-TOF and identified 17 proteins significantly
overexpressed in pregnancies complicated with inflam-
mation [54]. Peptide mass fingerprinting followed by
Western blotting and ELISA confirmed that five of the
biomarkers (human neutrophil defensins 1–3, and
calgranulin-A and -B) indicate intra-amniotic inflamma-
tion and allow the discrimination between PRL and
PROM. Furthermore, the authors applied the MR scoring
system to evaluate the diagnostic potential of the 4-peak
panel previously described.
Vuadens et al. identified new potential markers for
PROM [55]. Their study was based on 2-DE differential
display between AF and plasma samples in the 17th week
of gestation, followed by micro-sequencing analysis of
specific spots. Two peptides corresponding to the COOH-
terminus fragment of agrin and perlecan which were
present only in AF but absent from plasma samples of
pregnant women have been considered as possible
biomarkers for PROM. These results were further con-
firmed by Thadikkaran et al. [56]. Michel et al. applied
off-gel isoelectric focusing technique followed by tryptic
digestion of the proteins and by LC-MS/MS to analyze the
plasma and AF sample from a woman at pregnancy term
[18]. Systematic comparison revealed that nineteen pro-
teins were specifically present in the AF and absent in
maternal plasma. Among them ten had been previously
described as pregnancy or placenta specific and could
therefore be further characterized as potential PROM
biomarkers. No significant relationship, however regard-
ing the sensitivity, specificity and predictive value for the
accurate detection of women at risk for PROM has been
demonstrated up to now.
Concluding remarks and outlook
A number of putative biomarkers for fetal aneuploidies and
pregnancy complications have been discovered from
analysis of human AF. These biomarkers can be used to
discriminate cases complicated or women carrying chro-
mosomally abnormal fetuses, to provide insight into
involvement of pathophysiological pathways and may in
the future provide targets for therapeutic intervention.
Although very promising, some of the candidate
biomarkers are relatively abundant, shared among differ-
ent types of pathologies and overexpressed in other
human diseases. Future validation of candidate bio-
markers on large independent patient cohorts is needed
to quantify protein biomarkers in a sufficient number of
samples and determine which may discriminate the
presence or absence of disease.
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